Zofran takes its toll on DRL in Q1
A drug for morning sickness has proved a bitter pill for Dr Reddy's Laboratories (DRL). Zofran was expected to bring in Rs 80 crore in revenues but it actually turned in only Rs 6.6 crore for the topline.Revenues were also down at Rs 1,201.8 crore against Rs 1,404.9 crore but profits were up 31 per cent at Rs 182.5 crore.
